| 5.4 0.09 (1.69%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.93 | 1-year : | 7.75 |
| Resists | First : | 5.93 | Second : | 6.63 |
| Pivot price | 5.74  |
|||
| Supports | First : | 4.8 | Second : | 3.99 |
| MAs | MA(5) : | 5.4 |
MA(20) : | 5.65 |
| MA(100) : | 5.66 |
MA(250) : | 6.2 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.9 |
D(3) : | 18.1 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 14.6 | Low : | 3.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CADL ] has closed above bottom band by 30.1%. Bollinger Bands are 21.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.51 - 5.53 | 5.53 - 5.56 |
| Low: | 5.27 - 5.3 | 5.3 - 5.32 |
| Close: | 5.36 - 5.39 | 5.39 - 5.44 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Thu, 23 Oct 2025
Candel Therapeutics, Inc. (CADL) Stock Analysis: A 263.93% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Tue, 21 Oct 2025
LifeSci Capital Initiates Coverage of Candel Therapeutics (CADL) with Outperform Recommendation - Nasdaq
Fri, 17 Oct 2025
Candel Therapeutics secures $130M to fund lead program – ICYMI - Proactive financial news
Tue, 14 Oct 2025
$130M term loan gives Candel Therapeutics $50M now to fund Phase 3 CAN-2409 in NSCLC - Stock Titan
Tue, 14 Oct 2025
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - Yahoo Finance
Mon, 13 Oct 2025
Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 41.9 (%) |
| Shares Short | 7,220 (K) |
| Shares Short P.Month | 7,270 (K) |
| EPS | -0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.4 % |
| Return on Equity (ttm) | -55.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.37 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -8.19 |
| PEG Ratio | 0 |
| Price to Book value | 3.29 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|